Ruiz FLG, Colín PRF, Corlay NIS, Lara MMC, Dueñas THJ

Language: Spanish
References: 29
Page: 25-32
PDF size: 77.66 Kb.

ABSTRACT

Background
Major Depressive Disorder (MDD) is a disease associated to emotional, vegetative and physical symptoms, including for the latter those pain-related symptoms. MDD has a high prevalence rate with a substantial burden of illness, and it expected that by 2020 it will become the second cause of world disability. The diagnosis of MDD is difficult due to the high prevalence of painful physical symptoms, and also due to the fact these symptoms are more evident that the embedded emotional ones. Over 76% of patients with MDD, report painful physical symptoms observed, like headache, abdominal pain, back pain and unspecific-located pain; observing these symptoms can even predict depression severity. In addition, the likelihood of psychiatric disease increases, importantly, with the number of physical symptoms observed; moreover, the remission of physical symptoms predicts the complete remission in MDD. We present an observational, prospective study to examine the clinical profile of Mexican outpatients suffering MDD and determine the relationship between depression severity, painful physical symptoms in quality of life and depression.
Methods
Adult patients with current episodes of MDD, treated with antidepressants were included. MDD was defined according to the criteria of the Statistical Manual of Mental Disorders – 4th Edition (DSM-IV) or in the International Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). Patients should have been free of depression symptoms prior to the current episode for at least 2 months. Duration of current episode should not exceed two years. Treatment-resistant patients and those with other psychiatric diagnosis were excluded. Treatment-resistance was defined as: a) a failure to respond to treatment when two different antidepressants were employed at therapeutic doses for at least four weeks each, b) when the subject was previously treated with IMAO inhibitors, c) when electro-convulsive therapy (ECT) was previously employed. Other exclusion criteria comprise previous or current diagnosis of schizophrenia, schizophreniform or schizoaffective disorder, bipolar disorder, dementia or mental impairment. Patients were selected in 34 centers in Mexico.
Patients were classified according to the presence (SFD+) or absence (SFD-) of painful physical symptoms using the Somatic Symptom Inventory (SSI); SFD+ was defined as scores ≥ 2 for the pain-related items in the SSI (items 2, 3, 9, 14, 19, 27 and 28). Visual Analogue Scale (VAS) quantified pain severity (cervical pain, headache, back pain, shoulder pain, interference of pain in daily activities and vigil-time with pain). HAMD17 and CGI-S determined depression severity, while the Quality of Life in Depression Scale (QLDS) quantified subjective well-being.
Linear regression models were employed to compare groups for VAS, HAMD₁₇, CGI-S, and QLDS, to fit the confusions or clinical predictors when needed. Proportions between groups were established with Fisher exact test or logistic regression. Significance levels were established at 0.005 due to the observational nature of the study. In the result tables, standard deviation (SD) is reported as a variation around the mean value as Mean ± SD, and 95% confidence intervals are denoted 95% IC.
Results
A total of 313 patients were enrolled in the study. All of the enrolled patients were Mexican, almost them were women and had at least a previous MDD episode. Painful physical symptoms were reported by 73.7% of patients, these patients were classified into the SFD+ group. Neither statistical nor clinical significant differences between the SFD+ and SFD- groups were found when analyzing socio-demographic variables (age, gender, ethnical origin) and disease history variables (number of previous episodes of MDD, in the last 24 months, duration of current episode). At baseline, patients had a CGI-S mean score of 4.6 and HAMD17 of 26.3. HAMD17 mean score (27.1) in SFD+ patients was significantly higher (p‹0.0001) than the SFD- patients (23.8), but nonsignificant differences between groups were found for the subscales central, Maier & retard. CGI-S scores were similar between SFD+ and SFD-; 4.6 and 4.5 respectively (p›0.05). Prevalent painful physical symptoms were also the most painful, when a five-point scale was employed to measure severity, and comprised muscular pain (84.9%), cervical pain (84.2%) and headache (83.5%). SFD+ patients had higher pain severity in all VAS scales (p‹0.0001), with perceived severity scores twice as large when compared to SFDgroup. In particular, the global pain VAS reported average values of 49.0 and 19.7 for the SFD+ and SFD- groups respectively.
Patients came to the first psychiatric consultation treated with psychotherapy (27.9%), antidepressants (37.3%), anxiolytics (28.6%) and analgesics (9.7%); more than 50% of all patients were not taking any drugs or receiving psychotherapy for treatment of MDD at baseline. Analgesics were used only by 9.7% of patients for the treatment of painful physical symptoms in their current MDD episode. No significant differences between groups were found when comparing the use of psychotherapy, antidepressants, anxiolytics, antipsychotics, mood stabilizers or analgesics. Quality of life was poor for all patients, but significantly worse in the SFD+ group than in the SFD- group (QLDS scores of 23.2 and 20.0 respectively, p‹0.001).
Discussion:
The diagnosis and symptoms manifestation can be influenced by local socio-cultural factors, in particular cultural differences are associated with the prevalence of painful physical symptoms, but this finding is not consistent. The results of this study can be extrapolated to the MDD Mexican population, as selection criteria comprised only operative diagnosis criteria, and not enrollment into the study took place due to the presence of painful physical symptoms. Patients included into the study presented a moderate to severe disease as measured with the HAMD17 scores. The high prevalence of painful physical symptoms in patients with depression was confirmed in this study; it has been reported the patients report pain-related symptoms as the main (even the only) symptom when consulting general practitioners. Painful physical symptoms in MDD include headache, cervical pain, back pain or neck pain; the presence of painful physical symptoms in depression is associated to higher intakes medication, but in this study more than 50% of subjects were not receiving any treatment, including psychotherapy.
The treatment of MDD is by no means optimal, as only 30%- 40% of these patients reach complete remission of symptoms with their first antidepressant. Psychological symptoms respond to antidepressant treatment, but in general, this is not the case for the physical symptoms. The lack of efficacy can be explained as a failure in the treatment of these painful physical symptoms. Resolving these symptoms is even a predictor for the complete remission of MDD; the evidence might suggest that treatment of emotional and physical manifestations of depression could improve successful-treatment rates.
Conclusion:
As found in other reports, a high prevalence of painful physical symptoms was found in MDD patients. Increase in pain severity is associated with higher HAMD17 scores but not CGI-S scores; this discrepancy in the final rates obtained with both scales suggests that both emotional and physical dimensions of MDD should be considered when the clinical assessment is performed. We concluded that clinical judgment of Mexican psychiatrists differs between their global impression and a semi-structured interview in the same patient and therefore is fundamental that the clinical evaluation consists of both emotional and physical manifestations as important components of MDD.

REFERENCES

1. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders. Cuarta edición. Washington, 1994.

2. AWAD AG, VORUGANTI LN: Intervention research in psychosis: issues related to the assessment of quality of life. Schizophr Bull, 26:557-564, 2000.

3. AWAD AG, VORUGANTI LN: Quality of life and new antipsychotics in schizophrenia. Are patients better off ? Int J Soc Psychiatry, 45:268-275, 1999.

4. BRIDGES KW, GOLDBERG DP: Somatic presentation of DSM III psychiatric disorders in primary care. J Psychosomatic Research, 29:563-569, 1985.

5. CORRUBLE E, GUELFI JD: Pain complaints in depressed inpatients. Psychopathology, 33:307-309, 2000.

6. DELOACH LJ, HIGGINS MS, CAPLAN AB y cols.: The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesthesia Analgesia, 86:102-106, 1998.

7. DETKE MJ, LU Y, GOLDSTEIN DJ, MCNAMARA RK, DEMITRACK MA: Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatric Research, 36(6):383-390, 2002.

8. DEVINS GM, BEISER M, DION R y cols.: Cross-cultural measurements of psychological well-being: the psychometric equivalence of Cantonese, Vietnamese, and Laotian translations of the Affect Balance Scale. American J Public Health, 87:794-799, 1997.

9. ESCOBAR JI, GOMEZ J, TUASON VB: Depressive phenomenology in North and South American patients. American J Psychiatry, 140:47-51, 1983.

10. FAVA M: Depression with physical symptoms: treating to remission. J Clin Psychiatry, 64(Supl):7:24-28, 2003.

11. FRITZSCHE K, SANDHOLZER H, BRUCKS U y cols.: Psychosocial care by general practitioners—where are the problems? Results of a demonstration project on quality management in psychosocial primary care. International J Psychiatry Medicine, 29:395-409, 1999.

12. GERBER PD, BARRETT JE, BARRETT JA y cols.: The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen Intern Me, 7:170-173, 1992.

13. GREDEN JF: Physical symptoms of depression: unmet needs. J Clin Psychiatry, 64(Supl):7:5-11, 2003.

14. GREDEN JF: The burden of disease for treatment-resistant depression. J Clin Psychiatry, 62(Supl):16: 26-31, 2001.

15. GUY W: ECDEU Assessment Manual for Psychopharmacology – Revised (DHEW Publ No ADM 76-338). US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH. Psychopharmacology Research Branch, Division of Extramural Research Programs, (pp 218-222), Rockville, 1976.

16. HAMILTON M: A rating scale for depression. J Neurol Nurosurg Psychiatry, 23:56-62, 1960.

17. HUNT SM, MCKENNA SP: The QLDS: a scale for the measurement of quality of life in depression. Health Policy, 22:307-319, 1992.

18. IWATA N, BUKA S: Race/ethnicity and depressive symptoms: a cross-cultural/ethnic comparison among university students in East Asia, North and South America. Soc Sci Med, 55:2243-2252, 2002.

19. KATON WJ: Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry, 54:216-226, 2003.

20. KIRMAYER LJ, ROBBINS JM, DWORKIND M y cols.: Somatization and the recognition of depression and anxiety in primary care. American J Psychiatry, 150:734-741, 1993.

21. KROENKE K, SPITZER RL, WILLIAMS JB y cols.: Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med, 3:774-779, 1994.

22. MCKENNA SP: A new theoretical approach to the measurement of quality of life. Drug Information J, 28:13-18, 1994.

23. MURRAY CHRISTOPHER JL, LOPEZ AD (ed): The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Harvard University Press, Cambrige, 1996.

24. PARKER G, CHEAH YC, ROY K: Do the Chinese somatize depression? A cross-cultural study. Soc Psychiatry Psychiatr Epidemiol, 36:287-293, 2001.

25. PAYKEL ES, RAMANA R, COOPER Z y cols.: Residual symptoms after partial remission: an important outcome in depression. Psychol Med, 25:1171-1180, 1995.

26. SIMON GE, VONKORFF M, PICCINELLI M y cols.: An international study of the relation between somatic symptoms and depression. New England J Medicine, 341:1329-1335, 1999.

27. THASE ME, SIMONS AD, MCGEARY J y cols.: Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry, 149:1046-1052, 1992.

28. THASE ME: What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clinical Psychiatry, 63:95-103, 2002.

29. ULUSAHIN A, BASOGLU M, PAYKEL ES: A cross-cultural comparative study of depressive symptoms in British and Turkish clinical samples. Social Psychiatry Psychiatric Epidemiology, 29:31-39, 1994.